Anti-CD3-anti-CD19 bispecific monoclonal antibody

Drug Profile

Anti-CD3-anti-CD19 bispecific monoclonal antibody

Alternative Names: Monoclonal antibody SHR-1

Latest Information Update: 10 Apr 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Nonindustrial source
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors; CD3 antigen inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Lymphoid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Apr 2003 No development reported - Phase-I for Non-Hodgkin's lymphoma in Netherlands (IV-infusion)
  • 10 Apr 2003 No development reported - Phase-I for Non-Hodgkin's lymphoma in United Kingdom (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top